The OT-I microinjected model was developed by Dr. Francis Carbone of Monash Medical School and Dr. Michael Bevan of the University of Washington. The model was generated by injecting the rearranged T cell receptor Vα2-Jα26 (under the control of the alpha chain promoter and enhancer) and Vβ5-Dβ2-Jβ2.6 (under the control of the MHC class I promoter and the Ig heavy chain enhancer) into B6 x B6.C-H2bm1 blastocysts. Founders were subsequently bred to C57BL/6J mice for 9 generations. The line was later transferred to NIAID from Dr. Kristin Hogquist of the University of Minnesota and rederived by mating OT-I source males to C57BL/6NAi females. The transgenic mice were crossed twice to a homozygous C57BL/6J-Rag1tm1Mom knockout mouse which had been backcrossed 10 generations to B6/J (Mombaerts P, Cell 1992;68:869-877), and Rag1-/- offspring were selected. These mice were then intercrossed and OT-I TCR positive mice homozygous for the transgene were identified by test mating them to wild type partners and selecting animals that only gave rise to transgene positive offspring.
Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ and Carbone FR: T Cell receptor antagonist peptides induce positive selection; Cell 1994: 76:17-27
Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, Carbone FR, Heath WR.; Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001 166 :6099-6103.
Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S and Papaioannou VF: RAG-I deficient mice have no mature B and T cells. Cell 1992 68(5):869